Overview
* Prestige Q2 revenue of $274.1 mln beats analyst expectations despite a 3.4% decline yr/yr
* Adjusted EPS of $1.07 for Q2 beats analyst estimates
* Company repurchased 1.1 mln shares in Q2, enhancing shareholder value
Outlook
* Prestige maintains fiscal 2026 revenue outlook at $1,100 mln to $1,115 mln
* Company tightens fiscal 2026 adjusted EPS outlook to $4.54 to $4.58
* Prestige expects fiscal 2026 free cash flow of $245 mln or more
Result Drivers
* SUPPLY TIMING - Clear Eyes supply timing and retailer order timing helped surpass sales and earnings expectations
* LIMITED SUPPLY - Revenue decline driven by limited ability to supply demand for Clear Eyes in Ear & Eye Care category
* BRAND-BUILDING - Focus on brand-building and maintaining financial profile contributed to robust free cash flow
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q2 Beat $274.11 $257.13
Revenue mln mln (7
Analysts
)
Q2 Beat $1.07 $0.97 (7
Adjusted Analysts
EPS )
Q2 Net $42.21
Income mln
Q2 Gross $151.58
Profit mln
Q2 $71.91
Operatin mln
g
Expenses
Q2 $79.67
Operatin mln
g Income
Q2 $69.13
Pretax mln
Profit
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the pharmaceuticals peer group is "buy"
* Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc ( PBH ) is $80.00, about 25.2% above its November 5 closing price of $59.83
* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release:
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
